Mineralys Therapeutics Reports Q2 2026 Results; CMO Change

What Happened

• Mineralys Therapeutics, Inc. (MLYS) filed an 8-K on August 11, 2026 announcing its financial results for the quarter ended June 30, 2026 via a press release (Exhibit 99.1). The filing also discloses a leadership change in the company’s medical function: James J. Ferguson III, M.D., was appointed Chief Medical Officer effective August 10, 2026, replacing David Rodman, M.D.
• Dr. Rodman will remain with Mineralys full time as a Strategic Advisor. Following a Board review of his new responsibilities, the company determined he no longer meets the regulatory definitions of an “officer” or “executive officer” under Rules 16a‑1(f) and 3b‑7 of the Exchange Act. An amendment to Dr. Rodman’s employment letter reflecting the transition was executed on August 5, 2026 and is attached as Exhibit 10.1.

Key Details

• Filing date: August 11, 2026; quarter covered: ended June 30, 2026.
• Press release with quarterly results attached as Exhibit 99.1 to the 8‑K.
• James J. Ferguson III, M.D. named CMO, effective August 10, 2026.
• David Rodman, M.D. transitions to Strategic Advisor; amendment dated August 5, 2026 attached as Exhibit 10.1.

Why It Matters

• The 8‑K signals the company has provided its latest quarterly results (earnings/quarterly results) — investors should review the attached press release for revenue, profitability, cash runway, and clinical program updates.
• The CMO change is material for shareholders because it affects clinical leadership and program oversight; however, Dr. Rodman remains involved full time as a Strategic Advisor, indicating continuity in clinical strategy.
• Review the press release and the employment amendment (Exhibits 99.1 and 10.1) for full financial details and any specifics about management compensation or revised responsibilities.